The Binding Avidity of a Nanoparticle-Based Multivalent Targeted Drug Delivery Platform  by Hong, Seungpyo et al.
Chemistry & Biology
ArticleThe Binding Avidity of a Nanoparticle-Based
Multivalent Targeted Drug Delivery Platform
Seungpyo Hong,1,5 Pascale R. Leroueil,4,5 Istva´n J. Majoros,5 Bradford G. Orr,3,5 James R. Baker, Jr.,5,*
and Mark M. Banaszak Holl1,2,4,5,*
1Program in Macromolecular Science and Engineering
2Program in Biophysics
3Department of Physics
4Department of Chemistry
5Michigan Nanotechnology Institute for Medicine and Biological Sciences
University of Michigan, Ann Arbor, MI 48109, USA
*Correspondence: jbakerjr@umich.edu (J.R.B.), mbanasza@umich.edu (M.M.B.H.)
DOI 10.1016/j.chembiol.2006.11.015SUMMARY
Dendrimer-based anticancer nanotherapeutics
containing 5 folate molecules have shown
in vitro and in vivo efficacy in cancer cell target-
ing. Multivalent interactions have been inferred
from observed targeting efficacy, but have not
been experimentally proven. This study pro-
vides quantitative and systematic evidence for
multivalent interactions between these nanode-
vices and folate-binding protein (FBP). A series
of the nanodevices were synthesized by conju-
gation with different amounts of folate. Dissoci-
ation constants (KD) between the nanodevices
and FBP measured by SPR are dramatically
enhanced through multivalency (2,500- to
170,000-fold). Qualitative evidence is also pro-
vided for a multivalent targeting effect to KB
cells using flow cytometry. These data support
the hypothesis that multivalent enhancement of
KD, not an enhanced rate of endocytosis, is the
key factor resulting in the improved biological
targeting by these drug delivery platforms.
INTRODUCTION
Multivalent interactions, the simultaneous binding event
of multiple ligands to multiple receptors in biological sys-
tems, have been extensively investigated to promote tar-
geting of specific cell types [1–7]. These activities are also
central to a number of pathological processes, including
the attachment of viral, parasitic, mycoplasmal, and bac-
terial pathogens [8–13]. The design of synthetic systems
has been approached primarily through the development
of multivalent inhibitors. Studies with biological multiva-
lent inhibitors have yielded quantitative measurements
of binding avidities, with increases on the order of 1 to 9
orders of magnitude [14–18]. In contrast, synthetic multi-
valent effectors have exhibited much smaller improve-
ments in binding avidities, ranging from just 1 to 2 ordersChemistry & Biology 14, 107of magnitude. Design and implementation of effective
synthetic multivalent effector platforms capable of effec-
tively targeting desired cell types in vivo remain important
challenges.
Selective targeting of therapeutics to cancer cells is de-
sirable to improve treatment outcomes and to avoid toxic
side effects. The vitamin folic acid (FA), which has a high
affinity for the folate receptor (FAR), has been employed
as a specific targeting moiety [1] since FAR is overex-
pressed in many epithelial cancer cells, including breast,
ovary, endometrium, kidney, lung, head and neck, brain,
and myeloid cancers [19–22]. A variety of FA conjugates
and complexes have been developed for tumor-specific
targeting [2]. These include protein toxins [23], low molec-
ular weight chemotherapeutics [24], immunotherapeutic
agents [25], drug entrapped liposomes [26], and organic/
inorganic nanoparticles [3–5]. However, the affinities of
these folate targeting systems are limited by the number
of FAmolecules attached to the drugs and/or by the topol-
ogy of their chemical structures. This has, in some cases,
resulted in insufficient drug delivery efficiency to target
cancer cells [27]. The best directly measured results to
date employing multivalent FA conjugates showed 10-
to 100-fold enhancement over free FA [5].
Recently, a series of papers has been published de-
scribing the design, synthesis, in vitro cell experiments,
and mouse xenograft (KB cells) testing of a drug delivery
device based upon a generation 5 poly(amidoamine) (G5
PAMAM) scaffold, to which 5 folic acid molecules, dye,
and methotrexate had been conjugated [6, 28–30]. The
in vivo improvement in efficacy of this nanodevice over
free drug was attributed to a multivalent interaction be-
tween the multiple FA groups on the dendrimer periphery
with multiple high-affinity receptors on the tumor cell
surfaces. In order to test this hypothesis, a series of acet-
amide-terminated G5 dendrimer scaffolds containing
2–14 folic acid molecules and AlexaFluor 488 dye
(AF488) were synthesized (G5-Ac-AF488-FAx). Quantita-
tive measurements of KD were obtained for the interaction
of the devices with surface immobilized folate binding
protein (FBP) by using surface plasmon resonance (SPR).
Remarkably, these effector systems exhibit a 2,500- to–115, January 2007 ª2007 Elsevier Ltd All rights reserved 107
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Binding Avidity of a Multivalent Delivery PlatformFigure 1. Synthetic Scheme for G5
PAMAM Dendrimer-Based Nanodevices
with AF488 and Different Numbers of FA
Molecules
The number average molecular weights and
PDIs were determined by GPC. All numbers
of functional attachment were calculated from
GPC results. The total number of end groups
(110) was determined by potentiometric titra-
tion [40].170,000-fold enhancement of binding avidities as com-
pared to free FA. Qualitative studies of G5-Ac-AF488-
FAx to KB cells performed at 37 and 4
C and analyzed us-
ing a fluorescence activated cell sorter (FACS) showed the
same general trend in surface binding regardless of tem-
perature (low temperature prevents internalization but
not binding). The significance of this data is 3-fold: (1)
the ability of PAMAM dendrimer-based scaffolds to afford
a functional multivalent effector system is demonstrated;
(2) the in vivo effect is demonstrated to arise from the sub-
stantial enhancement of KD, not an increased rate of endo-
cytosis; and (3) the on-rate, ka, increases linearly with the
number of targeting agents and shows no cooperativity,
whereas the off-rate, kd, decreases exponentially with
the number of targeting agents.
RESULTS
Synthesis and Characterization of G5 PAMAM
Dendrimer-Based Nanodevices
The PAMAM dendrimer-based FAR targeting nanodevi-
ces were synthesized as summarized in Figure 1. AF488
was first attached to the partially acetylated G5 PAMAM
dendrimers, with a range of different numbers of FA then
attached to the dendrimer/AF488 conjugates, yielding
the dendritic nanodevice products. Since all the nanodevi-
ces were conjugated with the same number of AF488, dif-
ferences in fluorescence intensities from the nanodevices
in later FACS data can be regarded as a result of differ-
ences in nanodevice binding and/or uptake by KB cells.
As the last step of the synthesis, remaining terminal amine
groups were fully acetylated to prevent nonspecific elec-
trostatic interactions [31, 32]. This last step is particularly
important because remaining amine termini in the den-
drimers protonate at physiological pH and cause nonspe-
cific binding and uptake in vitro and in vivo as well as non-
specific binding with the carboxylate-terminated dextran
surface of the SPR sensor chips. Full acetylation is thus108 Chemistry & Biology 14, 107–115, January 2007 ª2007 Elsnecessary to accurately quantify the receptor-specific
interactions in both SPR and FACS studies. These den-
drimer nanodevices were characterized spectroscopically
using 1H NMR and UV/Vis as well as chromatographically
using GPC and HPLC (Table 1 and Figure 1; see Figures
S1, S2, S3, and S4 in the Supplemental Data available
with this article online). The nanodevices become more
polydisperse and ultimately give a bimodal distribution
as the number of attached FA increases. In the case of
G5-Ac-AF488-FA13.7, the polydispersity index (PDI) is
12.41 which is significantly greater than PDIs of previously
reported dendrimer conjugates. In accordance with this
finding, the full width at half-maximum of the HPLC peaks
also broadened as expected (see Figure S3) [33].
The mean number of FA per dendrimer was calculated
from GPC data as shown in Table 1. UV/Vis measure-
ments were consistent with an increasing amount of FA
per dendrimer but were systematically lower than the
GPC values. The FA is confined to the dendrimer surface,
creating an effectively higher local concentration, and thus
shows an expected deviation from Beer’s Law.
Quantitative Binding Avidities between
the Nanodevices and Surface-Bound FBP
Measured Using Surface Plasmon Resonance
Dissociation constants (KD) for the binding of G5-Ac-
AF488-FAx nanodevices with surface-bound FBP are
listed in Table 2 (for the SPR sensorgram traces, see Fig-
ure S7). KD of free FA wasmeasured to be53 106 M, in
good agreement with a previously reported value (11 3
106 M) obtained by SPR [5]. Our negative control (G5-
Ac-AF488) without targeting moiety FA shows no specific
or nonspecific binding, indicating the nontargeted nano-
devices do not significantly interact with the carboxylated
dextran surface of the sensor chip or the FBP immobilized
channel. When employing G5-Ac-AF488-FA2.6, a signifi-
cant degree of binding in the channel with immobilized
FBP was observed, whereas no detectable binding tookevier Ltd All rights reserved
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face). Themeasured KD is23 109M, which is a2500-
fold increase in avidity per dendrimer particle or a 1000-
fold increase in binding avidity as a function of total FA
concentration. The G5-Ac-AF488-FA4.7 device exhibited
per particle binding avidity improvements of two orders
of magnitude enhancement in the KD value (7 3 1011
M) as compared to theG5-Ac-AF488-FA2.6 and five orders
of magnitude improvement as compared to free FA. Fur-
ther increasing the number of FAs (7.2, 11.5, and 13.7)
conjugated to the nanodevices did not produce similar in-
creases in the magnitude of binding avidities. Instead,
Table 1. Calculation of Numbers of FA Attached on
a Dendrimer Molecule Determined by GPC and UV
Nanodevicesa
Nominal Equiv.
#FA Added for
FA Conjugation
#FA
(GPC)b
#FA
(UV)c
G5-Ac-AF488-FA0 0 — —
G5-Ac-AF488-FA2.6 3 2.6 1.3 ± 0.3
G5-Ac-AF488-FA4.7 6 4.7 3.0 ± 0.2
G5-Ac-AF488-FA7.2 9 7.2 5.3 ± 0.2
G5-Ac-AF488-FA11.5 12 11.5 8.3 ± 0.9
G5-Ac-AF488-FA13.7 15 13.7 10.6 ± 1.8
a The subscripted numbers of FA are the values determined by
GPC in the third column.
b The numbers were calculated by dividing the molecular
weight difference by the molecular weight of free FA.
c The numbers were determined by UV from two sets of data.
The calculation was performed by comparing UV absorbance
of the nanodevices with a standard curve made by the absor-
bance of free FA at different concentrations. The values were
averaged from the two sets of data and are presented with
standard deviations.
Table 2. Quantified Binding Constants of the Dendritic
Nanodevices with FBP Measured by SPR
Targeted
Nanodevice
Dissociation
Constant
KD (M)
a
Fold
Increase
over Free
FAb
Fold
Increase
over Free
FAc
Free FA 5 ± 3 3 106 — —
G5-Ac-AF488-FA2.6 2 ± 1 3 10
9 2,500 1,000
G5-Ac-AF488-FA4.7 7 ± 6 3 10
11 71,400 15,200
G5-Ac-AF488-FA7.2 7 ± 2 3 10
11 71,400 9,900
G5-Ac-AF488-FA11.5 5 ± 1 3 10
11 100,000 8,700
G5-Ac-AF488-FA13.7 3 ± 2 3 10
11 166,700 12,200
aObtained by averaging at least three different runs of SPR
measurements. The values are averages ± standard devia-
tions taken from different runs.
b Fold increase based on dendrimer concentrations. Also
known as multivalency parameter b.
c Fold increase based on FA concentrations.Chemistry & Biology 14, 107–more modest gains related to the simple increase in total
FA concentration were achieved (Figure 2). None-
theless, the lowest KD observed (G5-Ac-AF488-FA13.7) is
170,000 times lower than the KD of free FA.
Binding of the Nanodevices with
FAR-Overexpressing KB Cells: FACS and CLSM
A confocal image of KB cells incubated with G5-Ac-
AF488-FA4.7 indicates that the nanodevices bind to the
cell surface but do not substantially internalize into the
KB cells after 1 hr incubation at 37C (Figure 3). Concentra-
tion-dependent cellular binding of the G5-Ac-AF488-FAx
nanodevices to FAR-overexpressing KB cells was as-
sessed by FACS. As shown in Figure 4A, G5-Ac-AF488-
FA2.6 exhibits a lower degree of binding after incubation
with KB cells at 37C for 1 hr than the rest of the nanode-
vices. This trend is consistent with the differences in KD
measured by SPR. Additional binding experiments were
carried out at 4C to explore the possible role of FAR
membrane mobility on the measured binding constant.
The identical behavior observed for cells at 37C and 4C
suggests that the dendrimer conjugates interact with FAR
that are preorganized on the cell membrane surface and
that they do not assemble to form a preferred geometry
in response to the G5-Ac-AF488-FAx nanodevices.
To further compare the SPR results and the in vitro
FACS results, a plot of cellular binding (FACS) and associ-
ation constant KA (SPR) against the number of FA per
dendrimer molecule is shown in Figure 2. The KA and
mean fluorescence both initially increase significantly
as a function of number of FAs attached to the dendrimer.
Figure 2. Comparison of the Model Study Using SPR and the
In Vitro Study Using FACS of the Effect of the Number of FA
per Dendrimer Molecule upon Binding Constant
Note that blue circles and red squares represent SPR and FACS re-
sults, respectively. The error bars represent standard deviations. The
nanodevice with 2.6 FA shows a lower degree of cellular binding and
association constant KA than the rest of the nanodevices. FACS data
were obtained after incubation with dendritic nanodevices with FAR-
overexpressing KB cells at 37C and represent averaging from 12 dif-
ferent samples at each condition. Association constants were aver-
aged values from at least three SPR measurements for each point.
The association constant (KA =1/KD) is plotted in this case as it pro-
vides the best visual comparison to the FACS data.115, January 2007 ª2007 Elsevier Ltd All rights reserved 109
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AF488-FA4.7, after Incubation with KB
Cells at 37C for 1 hr
Green fluorescence comes from AlexaFluor
488 (AF488) attached to the dendritic nanode-
vices, and blue fluorescence is cell nuclei
stained by DAPI. Note that after 1 hr the den-
drimers have bound to the cell surface but
have not substantially internalized. This has
been confirmed by independent Z stack confo-
cal fluorescence microscopy images. Scale
bar: 10 mm.However, beginning with 7.2 FA per dendrimer, a plateau
is also observed for cellular binding.
Quantitative Measurement of the On-Rate and
Off-Rate Constants between the Nanodevices
and Surface-Bound FBP Measured Using
Surface Plasmon Resonance
In addition to quantitative measurement of KD or KA, which
can be conveniently compared to the cell binding data de-
termined by FACS, the SPR sensorgrams can also be
analyzed to quantitatively determine the on-rates (ka) and
off-rates (kd) for the nanodevices with the immobilized
FBP. The on-rates were observed to increase linearly
with the number of folic acids present on dendrimer. The
off-rates were observed to decrease exponentially with
an increase in the number of folic acids present. The de-
pendence of both rate constants on the number of folic
acids per dendrimer is illustrated in Figure 5.
DISCUSSION
Designed multivalent targeting systems offer great prom-
ise for enhancing the therapeutic index of a wide range of
drugs [2, 4, 6, 24, 26, 36]. Particularly, multivalently target-
ing devices can provide dramatic improvements in avidity
by enhancing the resident time of the drug on the cell tar-
get [29]. The 2,500- to 170,000-fold improvements in
binding avidity as measured by KD are, to the best of our
knowledge, the most potent demonstration to date of
a multivalent effector system. As already noted, this dra-
matic improvement in KD has already been shown to110 Chemistry & Biology 14, 107–115, January 2007 ª2007 Elstranslate into an ability to selectively target and kill FAR-
bearing cancer cells both in vitro and in vivo [6, 29, 37, 38].
The cooperativity of a multivalent system can be de-
fined as shown in Equation (1), where K is the dissociation
constant,N is the number of ligands, and a is the degree of
cooperativity.
KmultiN = ðKmonoÞaN (1)
Multivalent interactions are defined as positively coop-
erative for a > 1, noncooperative for a = 1, and negatively
cooperative for a < 1. The data presented in this paper
show Kmono = 5 3 106, K2.6 = 2 3 10
9, and K4.7 = 7 3
1011, which is K2.6 < (K
mono)2.6 and K4.7 < (K
mono)4.7 (Table
2). Thus, G5-Ac-AF488-FAx is a negatively cooperative
multivalent system as anticipated based upon the results
obtained from all other experimental multivalent systems
to date [10]. The data can also be considered using the
alternative multivalency parameter b as indicated in
Equation 2 [10].
KmultiN = bK
mono (2)
Our empirical measurements exhibit b(K2.6) = 2,500,
b(K4.7) = 71,000, b(K7.2) = 71,000, b(K11.5) = 100,000, and
b(K13.7) = 170,000 as shown in Table 2, consistent with a
multivalent interaction.
The SPRdata can be further analyzed in terms of the on-
rate (ka) and the off-rate (kd) of the dendrimer with the FBP
surface (Figure 5). The linear increase in ka as a function of
number of folic acid ligands indicates that the association
to the surface does not exhibit any cooperativity orevier Ltd All rights reserved
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Binding Avidity of a Multivalent Delivery PlatformFigure 4. Binding and Uptake of Dendritic Nanodevices by FAR-Overexpressing KB Cells Measured by FACS
(A–C) Concentration-dependent binding and uptake of nanodevices (A) at 37C for 1 hr and (B) at 4C for 1 hr. The same experiment with (A) at the 50
and 100 nM concentrations is repeated 12 times and (C) includes all the data points from the repetitions of the experiment at 37C for 1 hr.
(D) Time-dependent binding and uptake of dendritic nanodevices by FAR-overexpressing KB cells after 6, 12, and 24 hr incubations. The longer in-
cubation times demonstrate that the endocytosis rates of the dendritic nanodevices are similar regardless of the FA/dendrimer ratio. The error bars
represent standard deviations.multivalency. The exponential decrease in kd as a function
of the number of folic acids per dendrimer clearly demon-
strates the multivalency effects upon dissociation from
surface. This analysis demonstrates that the nonlinear
behavior of the equilibrium constant (KD in Table 2 or KA
in Figure 2) arises from the effects of multivalency upon
dissociation, not association, of the targeted dendrimer
with the FBP.
In order to better understand the saturation behavior
observed for the binding avidity, the number of FBP per
unit surface area on the SPR sensor chip was calculated.
The density of FBP immobilized on the chip wasmeasured
to be 8 ng/mm2. Based upon the 30 kDa molecular weight
of FBP, this translates into 16 molecules/100 nm2. Our
previously reported experimental and theoretical work
on dendrimer deformation on surfaces [34] indicates that
a G5 PAMAM dendrimer molecule can deform to a disc-
like structure with a radius of 4.8 nm or exhibit a maximum
surface area of 72 nm2. Based upon themeasured surfaceChemistry & Biology 14, 107–density of FBP and the footprint of the deformed G5
PAMAM dendrimer, a maximum of 12 FBP molecules
can theoretically interact per G5-Ac-AF488-FAx molecule.
The actual number of FBP molecules capable of an opti-
mal binding interaction should be lower than 12 since
the conformation of the FBP was not controlled. Thus,
the saturation behavior observed in the SPR experiments
is roughly consistent with the maximum number of prop-
erly oriented FBPs expected in an individual dendrimer’s
area of interaction.
The FACS experiments utilizing KB cells also showed
a saturation behavior. Calculation of the number of FAR
per unit area on a KB cell was carried out employing two
assumptions: (1) the exposed surface of a KB cell can
be computed as a spherical cap, and (2) every FAR recep-
tor is present on the surface of the exposed apical cap.
The number of FAR on a KB cell is roughly 2,400,000, ac-
cording to previous measurement (T. Thomas and J.R.B.,
unpublished data) [35]. Given a surface area of a single KB115, January 2007 ª2007 Elsevier Ltd All rights reserved 111
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FAR density is roughly 1/200 nm2. Although the ‘‘average’’
computed density of FAR on a KB cell is much lower than
that of FBP on the chip, recall that FAR distribution on the
cell surface is known to be heterogeneous [20, 21]. There-
fore, the saturation behavior observed on the cell surface
is occurring within a physically reasonable range of FAR
surface concentration, and is likely dependent on the FA
density on the dendrimer, the total surface area reach of
each dendrimer particle, and the closest packing of FAR
possible on the cell surface.
The average effective spacing of FA on the dendrimer
particle changes as a function of the degree of FA conju-
gated. Roughly speaking, it is the surface area presented
by the G5 dendrimer, 72 nm2, divided by the number of FA
conjugated to the dendrimer to give 28, 15, 10, 6, and
5 nm2, respectively, as the average effective spacing.
There is no detailed structure for FAR, however it is be-
lieved to be 30 kDa [39]. Assuming a density of 1.35
g/ml and a globular shape, this roughly corresponds to
a volume of37 nm3, a projection onto the dendrimer sur-
face of13 nm2, or a diameter of4 nm. Thus, a given G5
PAMAM dendrimer particle could not reasonably accom-
modate more than 72/13 or 5–6 FAR unless the plasma
membrane deformed about the dendrimer particle. Thus,
the saturation of binding effect does occur about where
one could reasonably expect the maximum number of
FAR interactions per dendrimer particle.
It is also interesting to note the same saturation behavior
is observed for data obtained at 4C, where rapid diffusion
of receptors in the membrane is not expected. The aver-
age spacing of FAR in the membrane is estimated to be
1/200 nm2, not the 1/13 nm2 suggested by the satura-
tion behavior. This suggests that at least 5–6 folic acid re-
ceptors are aggregated in themembrane in apreorganized
fashion and that the dendrimer complex does not recruit
receptors via a diffusional membrane process.
Figure 5. Association Rate Constant and Dissociation Rate
Constant of Dendrimers with Varying Numbers of Folic Acid
as Measured by SPR
The association rate constant (ka) (M
1s1) value increases linearly
with the number of folic acids per dendrimer whereas the dissociation
rate constant kd (s
1) value decays exponentially with the increasing
number of folic acid ligands. The error bars are standard errors of
the mean fromR3 runs.112 Chemistry & Biology 14, 107–115, January 2007 ª2007 ElsWe believe two related properties of the PAMAM den-
drimer scaffolds likely play a key role in allowing the mul-
tiple FA/FAR interactions required to achieve efficientmul-
tivalent interactions. First, the geometry of the dendrimer
preorganizes the targeting ligands into a small region of
space as compared to what is obtained if one conjugates
the targets to a similar molecular weight linear polymer.
Thus, one has ‘‘prepaid’’ the entropy penalty for localizing
the targeting ligands. Second, the dendrimer structure al-
lows all targeting ligands to address the cell surface [34].
This is not necessarily the case for a similar molecular
weight hyperbranched polymer in which tangled or cross-
linked chains may prevent the needed ligand orientation.
PAMAM dendrimers are quite flexible and easily deform
from the spherical shape adopted in isotropic media to
a disc-like structure upon interaction with a surface [34].
This combination of preorganization, polymer backbone
topology, and easy deformability all combine to make
the PAMAM dendrimer an effective material for achieving
multivalent binding to cell surfaces.
SIGNIFICANCE
A quantitative and systematic study of the multivalent
effect for folic acid-targeted dendritic nanodevices is
presented. A dramatic enhancement of binding avidity
(up to 170,000 fold) is measured, although the rate of
cellular internalization remained unchanged. Thus, the
key factor in the previously reported tumor reduction
is the enhanced residence time of the material on the
cell, leading to greater incorporation, not binding
followed by an enhanced rate of endocytosis. The
multivalent effector system described herein exhibits
a binding avidity improvement of 5 orders of magni-
tude, which represents a substantial advance over
the 1–2 orders of magnitude previously reported. The
study indicates that the principles of multivalency
can be effectively employed to synthesize targeted
chemotherapeutics with avidities great enough to
give in vivo efficacy.
EXPERIMENTAL PROCEDURES
Materials
Folic acid (FA), folate binding protein extracted from bovine milk
(FBP), acetic anhydride, ethylenediamine,methanol, dimethylsulfoxide
(DMSO), penicillin/streptomycin, and fetal bovine serum were pur-
chased from Sigma-Aldrich (St. Louis, MO). AlexaFluor 488 carboxylic
acid linked by succinimidyl ester (AF488), Trypsin-EDTA, Dulbecco’s
PBS, and RPMI 1640 (with and without folic acid) were supplied by
Invitrogen (Gaithersburg, MD).
Preparation of G5 PAMAM-Based Cancer Cell
Targeting Nanodevices
A G5 PAMAM dendrimer was synthesized and purified to remove low
molecular weight impurities as well as high molecular weight dimers
according to our previous reports [29–31]. After purification, G5
PAMAM dendrimers were partially acetylated (70 of the 110 total
primary amines), resulting in G5-Ac70 [40]. The remaining 40 primary
amine groups were used for reaction to further functionalize the
dendrimers. Note that a G5 PAMAM dendrimer molecule hasevier Ltd All rights reserved
Chemistry & Biology
Binding Avidity of a Multivalent Delivery Platformapproximately 110 primary amine termini according to our previous
titration measurement [40].
To fluorescently label the dendrimers, AF488 dissolved in DMSO
was added to the dendrimer/H2O solution at a molar ratio of 5:1
(AF488:dendrimer) in the presence of 1 M NaHCO3 and the reaction
mixture was stirred at RT for 48 hr. The resulting mixture of the den-
drimer conjugate (G5-Ac70-AF488) was then dialyzed in water for
2 days and lyophilized for 2 days, followed by 10 cycles of ultrafiltration
with PBS (with Ca2+ and Mg2+) and water using a 10,000 molecular
weight cut-off membrane at 21C, 5000 rpm for 30 min each.
G5-Ac70-AF488 conjugate in H2O was then reacted with FA preacti-
vated by 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide/HCl (EDC)
in DMF/DMSO at different molar ratios (3:1, 6:1, 9:1, 12:1, 15:1) of
FA to G5-Ac70-AF488. The same purification process was carried
out as described in the AF488 conjugation. Lastly, full acetylation of
the remaining primary amine group was completed [40], yielding our
final products G5-Ac-AF488-FA0, G5-Ac-AF488-FA2.6, G5-Ac-AF488-
FA4.7, G5-Ac-AF488-FA7.2, G5-Ac-AF488-FA11.5, and G5-Ac-AF488-
FA13.7. Note that the numbers in subscript following FA in the
dendrimer nomenclature are determined by GPC results in Table 1.
Characterization of G5 PAMAM-Based Cancer Cell
Targeting Nanodevices
1H NMR spectra were taken in D2O and were used to provide integra-
tion values for structural analysis using a Bruker AVANCE DRX 500 in-
strument following the same method described earlier [40, 41]. UV/Vis
spectra of the dendrimer conjugates were measured on a Perkin Elmer
UV/Vis spectrometer Lambda 20 (Wellesley, MA). The standard curve
for concentration was determined using free, molecular FA. This
causes the dendrimer-FA conjugates to appear artificially low due to
the expected deviation in Beer’s Law for these spatially constrained
samples. HPLC and GPC measurements were performed according
to the general methods previously reported [32, 33]. GPC experiments
were performed using an Alliance Waters 2695 separations module
(Waters Corp., Milford, MA) equippedwith aWaters 2487 dual-channel
UV detector (Waters Corp.), a Wyatt Dawn DSP laser photometer
(Wyatt Technology Corp., Santa Barbara, CA), an Optilab DSP interfer-
ometric refractometer (Wyatt Technology Corp.), and TosoHaas TSK-
Gel (Tosoh Bioscience LLC, Montgomeryville, PA) Guard PHW (75 3
7.5 mm, 12 mm), G 2000 PW (300 3 7.5 mm, 10 mm), G 3000 PW
(300 3 7.5 mm, 10 mm), and G 4000 PW (300 3 7.5 mm, 17 mm) col-
umns. Column temperatures were maintained at 25 ± 0.2C with a
Waters temperature control module. Citric acid buffer (0.1 M) with
0.025% sodium azide in water was used as a mobile phase. The pH
of the mobile phase was adjusted to 2.74 using NaOH, and the flow
rate was maintained at 1 ml/min. Sample concentration was approxi-
mately 2mg/ml, and an injection volume of 100 ml was used for all sam-
ples. Molar mass moments of the polymers were determined using
Astra software (version 4.9) (Wyatt Technology Corp.). Polyethylene
glycol (PEG) with molecular weight of 15 kDa (Sigma-Aldrich, St. Louis,
MO) was used as a standard to confirm the accuracy of the results. Al-
ternatively, G5 PAMAMdendrimer prepared atMNiMBSwas also used
to crosscheck the obtained molecular weight data. Additional details
regarding the HPLC experiments are provided with the chromato-
grams in the supplementary information.
Surface Plasmon Resonance Measurements
To study the interaction of FA-conjugated G5 PAMAM-based nanode-
vices (G5-Ac-AF488-FAx: x = 2.6, 4.7, 7.2, 11.5, or 13.7) with the FBP,
the surface plasmon resonance (SPR) technique using BIAcore X
(Pharmacia Biosensor AB, Uppsala, Sweden) was employed. FBP
was immobilized on the sensor chip surface (channel 2) of a carboxyl-
ated dextran-coated gold film (CM 5 sensor chip) by amine coupling as
described elsewhere [3–5, 42]. Briefly, 70 ml of a mixed solution of
NHS/ECD (1:1, v/v) was first injected into the BIAcore to activate the
carboxylated dextran, followed by injection of 70 ml of 2.5 mg/ml
FBP dissolved in 100 mM potassium phosphate buffer (pH 5.0), sup-
plemented with 4 mM mercaptoethanol and 10% (v/v) glycerol. 1 MChemistry & Biology 14, 107–ethanolamine in water (pH 8.5) was then injected to deactivate residual
NHS-esters on the sensor chip. The immobilization process was
performed at a flow rate of 10 ml/min, resulting in the binding of
8 ng/mm2 (8000 RU) of FBP per channel. The dendritic nanodevi-
ces (30 ml) were injected at concentrations of 500 nM, 1 mM, and
2 mM at a flow rate of 10 ml/min, allowing the nanodevices to flow in
both channels (channel 1 for reference and channel 2 with FBP) for 3
min. The final SPR sensorgrams were obtained from the signals from
channel 2 subtracted by those from channel 1. Binding parameters
of free FA with FBP were evaluated by the same condition but at differ-
ent concentrations (1 and 2 mM used for free FA). After each measure-
ment, 5 ml of 10 mM glycidol-HCl at pH 1.5 was injected to regenerate
the surface of the chip. It should be noted that we use term affinity for
monovalent systems and avidity for multivalent systems in this paper.
The binding curves were fit using the 1:1 Langmuir binding model in
BIAevaluation software. Associations and dissociations were fit sepa-
rately since there was turbulence in the curves between association
and dissociation phases in the process of subtracting signals from
the reference channel. Dissociation constants (KD) for each dendrimer
were obtained by averaging at least three different sets of results which
had c2 values lower than 3.0. All runs were independently analyzed for
errors associated with mass transport by exporting the data files to
Excel and plotting dR/dt versus R following the analysis described
by Glaser [43]. All of the resulting plots showed excellent linearity
and no evidence of the negative curvature associated with mass trans-
port. For all experiments, the analyte concentrations were greater than
the measured KD values by 3–4 orders of magnitude, verifying that the
first derivative plots were a meaningful method for ruling out mass
transport effects.
Cell Culture and Flow Cytometry (Fluorescence Activated
Cell Sorter: FACS) Measurements
The KB cell line was purchased from the American Type Tissue Collec-
tion (ATCC, Manassas, VA) and grown continuously as a monolayer at
37C and 5% CO2 in RPMI 1640 medium (Mediatech, Herndon, VA).
The RPMI 1640 medium was supplemented with penicillin (100 units/
ml), streptomycin (100 mg/ml), and 10% heat-inactivated fetal bovine
calf serum (FBS) before use. KB cells were cultured in RPMI 1640
medium without folic acid (Mediatech) for at least 4 days before exper-
iments, resulting in the folic acid receptor overexpressing KB (FAR-KB)
cell line.
For the FACS measurements, the FAR-KB cells were seeded on a
24-well plate for tissue culture at a concentration of 2 3 105 cells/
well and grown in folic acid deficient RPMI 1640 media (Mediatech,
Herndon, VA) at 37C, 5%CO2 for 24 hr. The cells were then incubated
with the series of the prepared nanodevices at either 37C or 4C for
1 hr. After removal of supernatants, cells were trypsinized and col-
lected into FACS tubes, followed by centrifugation at 1500 rpm for
5 min to obtain cell pellets. The pellets were washed with PBS (Ca2+,
Mg2+) twice using a repetitive centrifugation and resuspension process
and then finally resuspended in PBS with 0.1% bovine serum albumin.
The FACS sample preparation was performed on ice to inhibit cellular
reactions such as further uptake. Fluorescence signal intensities from
the samplesweremeasured using a Coulter EPICS/XLMCLBeckman-
Coulter flow cytometer, and data were analyzed using Expo32 soft-
ware (Beckman-Coulter, Miami, FL) [32].
Confocal Laser Scanning Microscopy (CLSM) Observation
FAR-KB cells were plated on a glass bottomed Petri dish. The cell cul-
ture medium was replaced by 2 ml of each dendrimer nanodevice so-
lution in PBS (Ca2+, Mg2+), followed by incubation at 37C under 5%
CO2 for 1 hr. The nanodevice-containing solution was removed, and
the resulting cell monolayer was washed with PBS at least three times.
Cells were fixed with 2% formaldehyde in PBS at room temperature for
10 min and then washed twice with PBS. Cells were stained by DAPI
and conserved in an antiphotobleaching agent. Confocal images
were then taken on an Olympus FV-500 confocal microscope using
a 1003, 1.4 NA oil immersion objective. To visualize AF488 attached115, January 2007 ª2007 Elsevier Ltd All rights reserved 113
Chemistry & Biology
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citation, and the emission was filtered at 505–525 IF nm.
Supplemental Data
The Supplemental Data include figures showing 1H NMR, UV/Vis,
HPLC, and GPC results (Figures S1–S4) of the prepared dendrimer
nanodevices. Figures S5 and S6 show FACS and fluorescencemicros-
copy data, respectively, indicating that the targeted nanodevices spe-
cifically interact with target cells (FAR-overexpressing KB cells). The
SPR traces are shown in Figure S7. The Supplemental Data are avail-
able at http://www.chembiol.com/cgi/content/full/14/1/107/DC1/.
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